INVESTOR ALERT: Class Action Lawsuit Against Impax Laboratories, Inc. Filed by Glancy Binkow & Goldberg LLP
LOS ANGELES--(BUSINESS WIRE)--Glancy Binkow & Goldberg LLP, representing investors of Impax Laboratories, Inc. (“Impax” or the “Company”) (NASDAQ:IPXL), has filed a class action lawsuit in the United States District Court for the Northern District of California on behalf of a class (the “Class”) comprising purchasers of Impax securities between May 20, 2013 and July 28, 2014, inclusive (the “Class Period”).
Please contact Lesley Portnoy at (888) 773-9224 or (310) 201-9150, or at email@example.com to discuss this matter. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
Impax, a specialty pharmaceutical company, develops, manufactures and markets bioequivalent pharmaceutical products, and develops and markets branded products. The Company currently has one late-stage branded pharmaceutical product candidate being developed internally, RYTARY™ (IPX066), an extended-release capsule formulation of carbidopa-levodopa for the symptomatic treatment of Parkinson’s disease.
The Complaint alleges that throughout the Class Period, defendants made materially false and misleading statements regarding quality control matters at the Company’s Taiwan production facility. Specifically, defendants misrepresented and/or failed to disclose that: (1) the Company failed to maintain proper quality control and manufacturing practices at its Taiwan facility in violation of current Good Manufacturing Practices; (2) the manufacturing deficiencies at the Taiwan facility could have a material adverse impact on the Company’s ability to successfully launch RYTARY, and jeopardized the Company’s ability to manufacture, sell, and distribute generic pharmaceutical products; and (3), based on the foregoing, defendants lacked a reasonable basis for their positive statements about the Company and its outlook, including statements about its ability to launch RYTARY.
On July 29, 2014, Impax announced that the Food and Drug Admission had completed an inspection of the Company’s Taiwan facility, and that the agency issued a Form 483, stating that it had found “ten inspectional observations,” or deficiencies, at the Taiwan facility. On this news, shares of Impax declined $4.27 per share, 15.23%, to close on July 29, 2014, at $23.76 per share, on unusually heavy volume.
If you are a member of the Class described above, you may move the Court no later than October 14, 2014, to serve as lead plaintiff, if you meet certain legal requirements. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, at (310) 201-9150, by e-mail to firstname.lastname@example.org, or visit our website at http://www.glancylaw.com. If you inquire by email, please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.